

**ASX Announcement | 21 November 2023
Visioneering Technologies (ASX:VTI)**

Adjustment to Option Exercise Price

Visioneering Technologies, Inc. (ASX: VTI) ('**Visioneering**' or 'the **Company**'), producer of the NaturalVue® Multifocal 1 Day Contact Lenses, today advises in accordance with Listing Rule 3.11.2, that it has listed options (**Options**) on issue which, under Listing Rule 6.22.2 and their terms, require their exercise price to be adjusted as a consequence of the rights offering that closed on 6 November 2023 (**Rights Offering**).

Listing Rule 6.22 confers on an option the right to a change to its exercise price if there is a pro-rata issue (except a bonus issue). The reduction in exercise price to be applied as outlined in the formula in Listing Rule 6.22.2.

As a result of the recent Rights Offering, applying the formula in Listing Rule 6.22.2 requires a reduction in the exercise price of the Options.

Effective 30 November 2023, the exercise of the Options will be adjusted in accordance with their terms and the Listing Rules:

Number of Options	Expiry Date	Original Exercise Price	Adjusted Exercise Price
6,919,447	28 February 2024	A\$3.00	A\$2.99

Ends

This release was authorized by the COO and CFO, Brian Lane.

For more information, please contact:

Company	Investor and media relations
Brian Lane COO and CFO, Visioneering Technologies, Inc. Email: blane@vtivision.com	Haley Chartres H^CK Tel: +61 423 139 163 Email: haley@hck.digital

About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in presbyopia and myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's flagship product is the NaturalVue® (etafilcon A) Enhanced Multifocal 1-Day Contact Lens, an extended depth of focus lens that the Company believes is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit www.vtvision.com or call +1 844-884-5367, ext. 104.

Foreign ownership restrictions

VTI's CHESSE Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers that are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any

state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.